Ergoteles’s Fate Therapeutics FATE Stock Holding History

Ergoteles’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,911	Closed	-$147K	–	326
2023 Q2	$147K	Buy	+30,911	New	+$171K	0.01%	887
2022 Q1	–	Sell	-47,026	Closed	-$2.75M	–	1348
2021 Q4	$2.75M	Buy	+47,026	New	+$2.67M	0.11%	205
2021 Q3	–	Sell	-3,554	Closed	-$308K	–	1353
2021 Q2	$308K	Sell	3,554 -15,746	-82%	-$1.27M	0.01%	1058
2021 Q1	$1.59M	Buy	+19,300	New	+$1.85M	0.05%	313

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ergoteles's FATE Position: Q3 2023 in Review

Ergoteles sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 30,911 shares — an estimated $147K sold.

Ergoteles first reported a position in FATE in Q1 2021 and held it in 4 quarters. The position peaked at $2.75M in Q4 2021. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

Ergoteles reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 30,911 Fate Therapeutics shares in Q3 2023, an estimated $147K.
Ergoteles first reported a position in Fate Therapeutics in Q1 2021 and held it in 4 quarters.
Ergoteles's Fate Therapeutics position peaked at $2.75M in Q4 2021.
170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.